- Home
- GVH vs CNSP Comparison
GVH vs CNSP Comparison
Compare GVH & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GVH | CNSP |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.1M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GVH | CNSP |
|---|---|---|
| Price | $1.04 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $80.00 | $20.00 |
| AVG Volume (30 Days) | ★ 90.4K | 31.9K |
| Earning Date | 02-17-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.73 |
| 52 Week High | $10.74 | $10.59 |
Technical Indicators
Market Signals| Indicator | GVH | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 24.68 |
| Support Level | $0.88 | $0.77 |
| Resistance Level | $1.79 | $4.00 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 5.49 | 6.83 |
Price Performance
Historical ComparisonAbout GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.